We have located links that may give you full text access.
Vestibular schwannomas - when should conservative management be reconsidered?
British Journal of Neurosurgery 2010 April
OBJECTIVE: To document the natural history of vestibular schwannomas treated conservatively, and to find if there are any predictive factors for growth and need for active intervention.
DESIGN: A retrospective review of patient notes and radiology, mostly MRIs.
SUBJECTS: Eighty-eight patients managed conservatively for unilateral vestibular schwannoma and that have had at least two radiological investigations.
OUTCOME MEASURES: Change in tumour size over time was evaluated. Linear and logistic regression, respectively, were used to determine which factors (of age, size at diagnosis, audiology at presentation, length of follow-up or growth within first year of follow-up) would predict overall growth and active intervention. Characteristics of those that required active intervention is also demonstrated.
RESULTS: Of the 88 patients, the average size of schwannoma at diagnosis was 10.88 mm. The mean length of radiological follow-up was 3.65 years. 51.1% of schwannomas grew, 12.5% shrank and 36.4% remained the same size. The mean rate of growth was 1.24 mm per year. 25.0% failed conservative treatment, with 19 patients having stereotactic radiosurgery and three undergoing microsurgery. Only growth in the first year of follow-up was found to significantly predict total growth. Size at diagnosis and growth in first year of follow-up were significantly found to predict active intervention.
CONCLUSIONS: There remains a place for conservative treatment in those with small tumours, the elderly and those with significant co-morbidities. Growth in the first year of follow-up should be considered in determining whether to treat actively or not.
DESIGN: A retrospective review of patient notes and radiology, mostly MRIs.
SUBJECTS: Eighty-eight patients managed conservatively for unilateral vestibular schwannoma and that have had at least two radiological investigations.
OUTCOME MEASURES: Change in tumour size over time was evaluated. Linear and logistic regression, respectively, were used to determine which factors (of age, size at diagnosis, audiology at presentation, length of follow-up or growth within first year of follow-up) would predict overall growth and active intervention. Characteristics of those that required active intervention is also demonstrated.
RESULTS: Of the 88 patients, the average size of schwannoma at diagnosis was 10.88 mm. The mean length of radiological follow-up was 3.65 years. 51.1% of schwannomas grew, 12.5% shrank and 36.4% remained the same size. The mean rate of growth was 1.24 mm per year. 25.0% failed conservative treatment, with 19 patients having stereotactic radiosurgery and three undergoing microsurgery. Only growth in the first year of follow-up was found to significantly predict total growth. Size at diagnosis and growth in first year of follow-up were significantly found to predict active intervention.
CONCLUSIONS: There remains a place for conservative treatment in those with small tumours, the elderly and those with significant co-morbidities. Growth in the first year of follow-up should be considered in determining whether to treat actively or not.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app